nach oben

Pediatric Nephrology

Erschienen in:

01.09.2006 | Editorial Commentary

Cystatin C, kidney function and cardiovascular disease

verfasst von: Arend Bökenkamp, Stefan Herget-Rosenthal, Regina Bökenkamp

Erschienen in: Pediatric Nephrology | Ausgabe 9/2006

Einloggen, um Zugang zu erhalten

Abstract

Cystatin C, an endogenous low-molecular-weight marker of glomerular filtration rate, has recently been shown to be associated with future cardiovascular disease in healthy elderly populations and patients with documented atherosclerosis in a dose-dependent manner that possibly reflects a very early stage of chronic renal dysfunction. At the same time, local cystatin C deficiency has been demonstrated in atherosclerotic and aneurismal lesions, suggesting a protective role of cystatin C in the vessel wall, possibly in concert with TGF-β1. Although cystatin C is not an acute phase reactant, large epidemiological studies have documented a highly significant association between serum cystatin C and mildly increased C-reactive protein (CRP) levels, the hallmark of the chronic inflammatory state associated with atherosclerosis and chronic renal failure. Since cystatin C is produced by all nucleated cells, it is unlikely that local variations in cystatin C synthesis in diseased arteries – rather than global cystatin C production and renal elimination – should determine its serum concentration. Consequently, the present review proposes microinflammation as the unifying concept for both lines of evidence.

Manjunath G, Tighiouart H, Coresh J, Macleod B, Salem DN, Griffith JL, Levey AS, Sarnak MJ (2003) Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 63:1121–1129PubMedCrossRef

Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA (2004) Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 351:1285–1295PubMedCrossRef

Groothoff JW, Gruppen MP, Offringa M, Hutten J, Lilien MR, Van De Kar NJ, Wolff ED, Davin JC, Heymans HS (2002) Mortality and causes of death of end-stage renal disease in children: a Dutch cohort study. Kidney Int 61:621–629PubMedCrossRef

Ritz E (2003) Minor renal dysfunction: an emerging independent cardiovascular risk factor. Heart 89:963–964PubMedCrossRef

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Circulation 108:2154–2169PubMedCrossRef

Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060PubMedCrossRef

Shlipak MG, Katz R, Fried LF, Jenny NS, Stehman-Breen CO, Newman AB, Siscovick D, Psaty BM, Sarnak MJ (2005) Cystatin-C and mortality in elderly persons with heart failure. J Am Coll Cardiol 45:268–271PubMedCrossRef

Sarnak MJ, Katz R, Stehman-Breen CO, Fried LF, Jenny NS, Psaty BM, Newman AB, Siscovick D, Shlipak MG (2005) Cystatin C concentration as a risk factor for heart failure in older adults. Ann Intern Med 142:497–505PubMed

Fried LF, Katz R, Sarnak MJ, Shlipak MG, Chaves PH, Jenny NS, Stehman-Breen C, Gillen D, Bleyer AJ, Hirsch C, Siscovick D, Newman AB (2005) Kidney function as a predictor of noncardiovascular mortality. J Am Soc Nephrol 16:3728–3735PubMedCrossRef

10.

O’Hare AM, Newman AB, Katz R, Fried LF, Stehman-Breen CO, Seliger SL, Siscovick DS, Shlipak MG (2005) Cystatin C and incident peripheral arterial disease events in the elderly: results from the Cardiovascular Health Study. Arch Intern Med 165:2666–2670PubMedCrossRef

11.

Lin J, Knight EL, Hogan ML, Singh AK (2003) A comparison of prediction equations for estimating glomerular filtration rate in adults without kidney disease. J Am Soc Nephrol 14:2573–2580PubMedCrossRef

12.

Koenig W, Twardella D, Brenner H, Rothenbacher D (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51:321–327PubMedCrossRef

13.

Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L (2004) Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 110:2342–2348PubMedCrossRef

14.

Luc G, Bard JM, Lesueur C, Arveiler D, Evans A, Amouyel P, Ferrieres J, Juhan-Vague I, Fruchart JC, Ducimetiere P (2006) Plasma cystatin-C and development of coronary heart disease: The PRIME Study. Atherosclerosis 185:375–380PubMedCrossRef

15.

Albert MA, Rifai N, Ridker PM (2001) Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis. Vasc Med 6:145–149PubMedCrossRef

16.

Eriksson P, Deguchi H, Samnegard A, Lundman P, Boquist S, Tornvall P, Ericsson CG, Bergstrand L, Hansson LO, Ye S, Hamsten A (2004) Human evidence that the cystatin C gene is implicated in focal progression of coronary artery disease. Arterioscler Thromb Vasc Biol 24:551–557PubMedCrossRef

17.

Tenstad O, Roald AB, Grubb A, Aukland K (1996) Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 56:409–414PubMedCrossRef

18.

Jacobsson B, Lignelid H, Bergerheim US (1995) Transthyretin and cystatin C are catabolized in proximal tubular epithelial cells and the proteins are not useful as markers for renal cell carcinomas. Histopathology 26:559–564PubMedCrossRef

19.

Perrone RD, Madias NE, Levey AS (1992) Serum creatinine as an index of renal function: new insights into old concepts. Clin Chem 38:1933–1953PubMed

20.

Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O, Grubb A (1990) Structure and expression of the human cystatin C gene. Biochem J 268:287–294PubMed

21.

Bokenkamp A, Domanetzki M, Zinck R, Schumann G, Byrd D, Brodehl J (1998) Cystatin C – a new marker of glomerular filtration rate in children independent of age and height. Pediatrics 101:875–881PubMedCrossRef

22.

Price CP, Finney H (2000) Developments in the assessment of glomerular filtration rate. Clin Chim Acta 297:55–66PubMedCrossRef

23.

Oddoze C, Morange S, Portugal H, Berland Y, Dussol B (2001) Cystatin C is not more sensitive than creatinine for detecting early renal impairment in patients with diabetes. Am J Kidney Dis 38:310–316PubMedCrossRef

24.

Chantrel F, Agin A, Offner M, Koehl C, Moulin B, Hannedouche T (2000) Comparison of cystatin C versus creatinine for detection of mild renal failure. Clin Nephrol 54:374–381PubMed

25.

Laterza OF, Price CP, Scott MG (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48:699–707PubMed

26.

Dharnidharka VR, Kwon C, Stevens G (2002) Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 40:221–226PubMedCrossRef

27.

Perkins BA, Nelson RG, Ostrander BE, Blouch KL, Krolewski AS, Myers BD, Warram JH (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16:1404–1412PubMedCrossRef

28.

Herget-Rosenthal S, Marggraf G, Husing J, Goring F, Pietruck F, Janssen O, Philipp T, Kribben A (2004) Early detection of acute renal failure by serum cystatin C. Kidney Int 66:1115–1122PubMedCrossRef

29.

Herget-Rosenthal S, Pietruck F, Volbracht L, Philipp T, Kribben A (2005) Serum cystatin C–a superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol 64:41–46PubMed

30.

Filler G, Priem F, Lepage N, Sinha P, Vollmer I, Clark H, Keely E, Matzinger M, Akbari A, Althaus H, Jung K (2002) Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. Clin Chem 48:729–736PubMed

31.

Poge U, Gerhardt TM, Stoffel-Wagner B, Palmedo H, Klehr HU, Sauerbruch T, Woitas RP (2005) beta-Trace protein is an alternative marker for glomerular filtration rate in renal transplantation patients. Clin Chem 51:1531–1533PubMedCrossRef

32.

Pham-Huy A, Leonard M, Lepage N, Halton J, Filler G (2003) Measuring glomerular filtration rate with cystatin C and beta-trace protein in children with spina bifida. J Urol 169:2312–2315PubMedCrossRef

33.

Fliser D, Ritz E (2001) Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 37:79–83PubMedCrossRef

34.

Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K (2003) Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 42:36–43PubMedCrossRef

35.

Mitsnefes M, Kimbal T, Kartal J, Kathman T, Mishra J, Devarajan P (2006) Serum cystatin C and left ventricular diastolic dysfunction in children with chronic kidney disease: Ped Nephrol DOI 10.1007/s00467-006-0132-4

36.

Curhan G (2005) Cystatin C: a marker of renal function or something more? Clin Chem 51:293–294PubMedCrossRef

37.

Bjarnadottir M, Grubb A, Olafsson I (1995) Promoter-mediated, dexamethasone-induced increase in cystatin C production by HeLa cells. Scand J Clin Lab Invest 55:617–623PubMedCrossRef

38.

Risch L, Herklotz R, Blumberg A, Huber AR (2001) Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 47:2055–2059PubMed

39.

Fricker M, Wiesli P, Brandle M, Schwegler B, Schmid C (2003) Impact of thyroid dysfunction on serum cystatin C. Kidney Int 63:1944–1947PubMedCrossRef

40.

Randers E, Kristensen JH, Erlandsen EJ, Danielsen H (1998) Serum cystatin C as a marker of the renal function. Scand J Clin Lab Invest 58:585–592PubMedCrossRef

41.

Johnston N, Jernberg T, Lindahl B, Lindback J, Stridsberg M, Larsson A, Venge P, Wallentin L (2004) Biochemical indicators of cardiac and renal function in a healthy elderly population. Clin Biochem 37:210–216PubMedCrossRef

42.

Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE (2004) Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65:1416–1421PubMedCrossRef

43.

Hansson GK (2005) Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352:1685–1695PubMedCrossRef

44.

Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and epidemiology and prevention. Hypertension 42:1050–1065PubMedCrossRef

45.

Cengiz N, Baskin E, Agras PI, Sezgin N, Saatci U (2005) Relationship between chronic inflammation and cardiovascular risk factors in children on maintenance hemodialysis. Transplant Proc 37:2915–2917PubMedCrossRef

46.

Galteau MM, Guyon M, Gueguen R, Siest G (2001) Determination of serum cystatin C: biological variation and reference values. Clin Chem Lab Med 39:850–857PubMedCrossRef

47.

Abrahamson M, Barrett AJ, Salvesen G, Grubb A (1986) Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J Biol Chem 261:11282–11289PubMed

48.

Abrahamson M (1994) Cystatins. Methods Enzymol 244:685–700PubMed

49.

Turk V, Turk B, Guncar G, Turk D, Kos J (2002) Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul 42:285–303PubMedCrossRef

50.

Lerner UH, Johansson L, Ranjso M, Rosenquist JB, Reinholt FP, Grubb A (1997) Cystatin C inhibitor of bone resorption produced by osteoblasts. Acta Physiol Scand 161:81–92PubMedCrossRef

51.

Nakanishi T, Ozaki Y, Blomgren K, Tateyama H, Sugiura-Ogasawara M, Suzumori K (2005) Role of cathepsins and cystatins in patients with recurrent miscarriage. Mol Hum Reprod 11:351–355PubMedCrossRef

52.

Afonso S, Romagnano L, Babiarz B (1997) The expression and function of cystatin C and cathepsin B and cathepsin L during mouse embryo implantation and placentation. Development 124:3415–3425PubMed

53.

Wang B, Sun J, Kitamoto S, Yang M, Grubb A, Chapman HA, Kalluri R, Shi GP (2006) Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 281:6020–6029PubMedCrossRef

54.

Leung-Tack J, Tavera C, Martinez J, Colle A (1990) Neutrophil chemotactic activity is modulated by human cystatin C, an inhibitor of cysteine proteases. Inflammation 14:247–258PubMedCrossRef

55.

Leung-Tack J, Tavera C, Gensac MC, Martinez J, Colle A (1990) Modulation of phagocytosis-associated respiratory burst by human cystatin C: role of the N-terminal tetrapeptide Lys-Pro-Pro-Arg. Exp Cell Res 188:16–22PubMedCrossRef

56.

Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP (2004) Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 24:1359–1366PubMedCrossRef

57.

Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P (1998) Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 102:576–583PubMedCrossRef

58.

Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, Ridker PM, Libby P, Chapman HA (1999) Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 104:1191–1197PubMedCrossRef

59.

Sukhova GK, Wang B, Libby P, Pan JH, Zhang Y, Grubb A, Fang K, Chapman HA, Shi GP (2005) Cystatin C deficiency increases elastic lamina degradation and aortic dilatation in apolipoprotein E-null mice. Circ Res 96:368–375PubMedCrossRef

60.

Huh CG, Hakansson K, Nathanson CM, Thorgeirsson UP, Jonsson N, Grubb A, Abrahamson M, Karlsson S (1999) Decreased metastatic spread in mice homozygous for a null allele of the cystatin C protease inhibitor gene. Mol Pathol 52:332–340PubMed

61.

Bengtsson E, To F, Hakansson K, Grubb A, Branen L, Nilsson J, Jovinge S (2005) Lack of the cysteine protease inhibitor cystatin C promotes atherosclerosis in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 25:2151–2156PubMedCrossRef

62.

Bengtsson E, To F, Grubb A, Hakansson K, Wittgren L, Nilsson J, Jovinge S (2005) Absence of the protease inhibitor cystatin C in inflammatory cells results in larger plaque area in plaque regression of apoE-deficient mice. Atherosclerosis 180:45–53PubMedCrossRef

63.

Rao M, Guo D, Jaber BL, Tighiouart H, Pereira BJ, Balakrishnan VS (2004) Transforming growth factor-beta 1 gene polymorphisms and cardiovascular disease in hemodialysis patients. Kidney Int 66:419–427PubMedCrossRef

64.

Loew M, Hoffmann MM, Koenig W, Brenner H, Rothenbacher D (2005) Genotype and plasma concentration of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events. Arterioscler Thromb Vasc Biol 25:1470–1474PubMedCrossRef

65.

Eriksson P, Jones KG, Brown LC, Greenhalgh RM, Hamsten A, Powell JT (2004) Genetic approach to the role of cysteine proteases in the expansion of abdominal aortic aneurysms. Br J Surg 91:86–89PubMedCrossRef

66.

Kabanda A, Jadoul M, Pochet JM, Lauwerys R, van Ypersele de Strihou C, Bernard A (1994) Determinants of the serum concentrations of low molecular weight proteins in patients on maintenance hemodialysis. Kidney Int 45:1689–1696PubMedCrossRef

67.

Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41PubMedCrossRef

Titel: Cystatin C, kidney function and cardiovascular disease
verfasst von: Arend Bökenkamp
Stefan Herget-Rosenthal
Regina Bökenkamp
Publikationsdatum: 01.09.2006
Verlag: Springer-Verlag
Erschienen in: Pediatric Nephrology / Ausgabe 9/2006
Print ISSN: 0931-041X
Elektronische ISSN: 1432-198X
DOI: https://doi.org/10.1007/s00467-006-0192-5

Neu im Fachgebiet Pädiatrie

23.04.2024 | Typ-1-Diabetes | Nachrichten

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Cystatin C, kidney function and cardiovascular disease

Abstract

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 9/2006

Urolithiasis, idiopathic hypercalciuria and insularity

39th and 40th Annual Meeting of the Japanese Society for Pediatric Nephrology, 2004 and 2005

A new international classification of childhood vasculitis

IgA nephropathy in two adolescent sisters heterozygous for Fabry disease

Expression of P-glycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response

Lupus nephropathy and cardiopulmonary and hepatic dysfunctions in a child

Neu im Fachgebiet Pädiatrie

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Neue Studienergebnisse zur Myopiekontrolle mit Atropin

Spinale Muskelatrophie: Neugeborenen-Screening lohnt sich

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

Update Pädiatrie